Plain-English translation of NCT06811844 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether patients with advanced nasopharyngeal cancer can do just as well with a shorter course of chemotherapy combined with an immunotherapy drug called camrelizumab, compared to a longer chemotherapy course. Right now, doctors aren't sure if giving more chemotherapy cycles actually helps patients live longer or just causes more side effects.
Recent studies suggest that three cycles of chemotherapy may not help patients survive longer than two cycles, but it does cause more serious side effects like blood problems and stomach issues. This trial is testing whether the new treatment approach—using fewer chemotherapy cycles combined with immunotherapy—can work just as well while being easier on patients' bodies.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either two or three cycles of chemotherapy combined with the immunotherapy medication camrelizumab. The treatment will be given over several weeks at the hospital, with regular monitoring visits to check how well it's working and watch for side effects. Your doctors will use imaging scans and blood tests to track your progress throughout the study.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China